Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $300
Benzinga Newsdesk 6 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price target from $375 to $300.
Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price target from $375 to $300.